Metabolomic Biomarkers
Metabolomics—the comprehensive study of small molecule metabolites—has emerged as a promising approach to ME/CFS biomarker discovery.
1 Key Metabolomic Studies
1.2 Amino Acid Profile Abnormalities
Multiple studies report altered amino acids:
- Branched-chain amino acids: Often reduced
- Glutamine/glutamate: Altered ratios
- Tryptophan: Reduced (diverted to kynurenine pathway)
- Arginine: May be depleted (NO synthesis)
1.3 Lipid Metabolism Markers
Abnormal lipid profiles:
- Altered phosphatidylcholine species
- Abnormal ceramide levels
- Changed fatty acid profiles
- Reduced omega-3 fatty acids in some studies
1.4 TCA Cycle Metabolites
Krebs cycle abnormalities:
- Altered citrate, isocitrate, succinate levels
- Suggests impaired oxidative metabolism
- Correlates with mitochondrial dysfunction hypothesis
1.5 RBC Glutathione
Reduced glutathione is among the most replicated specific oxidative stress findings in ME/CFS, documented in both erythrocytes and brain tissue. Shungu et al. (2012) found significantly reduced cortical glutathione via MRS, correlating with physical functioning and energy levels, with pilot data showing NAC normalized glutathione and symptoms Clinical audits of mitochondrial support protocols in ME/CFS patients consistently identify glutathione depletion as part of the oxidative stress profile Glutathione functions both as a biomarker of oxidative burden and as a treatment target: N-acetylcysteine (NAC) is used to replenish glutathione precursors.
1.6 CoQ10 and Acylcarnitine Profile
Coenzyme Q10 (CoQ10) deficiency has been documented in ME/CFS: Maes et al. (2009) found that 44.8% of patients had plasma CoQ10 below the lowest control value, with lower CoQ10 correlating with fatigue, autonomic, and neurocognitive symptoms (\(n = 58\)) (Maes et al. 2009). CoQ10 has been proposed as both a biomarker of mitochondrial electron transport chain dysfunction and a candidate marker of treatment response in supplementation trials. A limitation of total plasma CoQ10 as a biomarker is that it cannot distinguish deficiency driven by oxidative consumption (infection-driven, with inflammation as a downstream amplifier; see Speculation Infection-Driven Oxidative Consumption as a Contributor to CoQ10 Depletion) from deficiency driven by impaired biosynthesis; the ubiquinol:ubiquinone redox ratio has been proposed as a measure that may distinguish consumption from biosynthesis when electron-transport-chain function is separately shown to be intact (Prediction The Ubiquinol:Ubiquinone Redox Ratio as a Consumption-Specific Biomarker, Open Question Is ME/CFS CoQ10 Deficiency Driven by Oxidative Consumption or Impaired Biosynthesis?). Acylcarnitine profiles reflect fatty acid beta-oxidation capacity via the carnitine shuttle. Long-chain acylcarnitines (C18:1, C18:2) are 30–40% lower in ME/CFS patients compared to controls, suggesting reduced carnitine palmitoyltransferase-I (CPT-I) activity and impaired mitochondrial fatty acid import. Reduced free carnitine and total carnitine are also documented, correlating with functional capacity.
2 Synthesis of Metabolomic Findings
2.1 Common Patterns
Despite methodological differences, several patterns emerge:
- Hypometabolic signature (reduced metabolites across pathways)
- Impaired energy metabolism
- Oxidative stress markers
- Altered lipid metabolism
2.2 Subgroup Differences
Metabolomic studies may identify subgroups:
- Different metabolic signatures in different patients
- Potential for metabolomics-based classification
- Treatment response prediction
2.3 Clinical Utility
Current status:
- Not yet validated for clinical diagnosis
- Research tool for understanding pathophysiology
- Potential for future diagnostic panels
- Requires standardization and replication